(−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane,...

Details (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane,... (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane,...

2006-05-09

2006-05-09

Solola, Taofiq (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07041835

ABSTRACT:
The present invention relates to (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.

REFERENCES:
patent: 3892722 (1975-07-01), Hoffman et al.
patent: 4022652 (1977-05-01), Hirano et al.
patent: 4088652 (1978-05-01), Fanshawe et al.
patent: 4118393 (1978-10-01), Fanshawe et al.
patent: 4118417 (1978-10-01), Epstein
patent: 4131611 (1978-12-01), Fanshawe et al.
patent: 4196120 (1980-04-01), Fanshawe et al.
patent: 4231935 (1980-11-01), Fanshawe et al.
patent: 4336268 (1982-06-01), Bruderer et al.
patent: 4435419 (1984-03-01), Epstein et al.
patent: 4504657 (1985-03-01), Bouzard et al.
patent: 4521431 (1985-06-01), Crookes
patent: 4591598 (1986-05-01), Urbach et al.
patent: 5039680 (1991-08-01), Imperato et al.
patent: 5075341 (1991-12-01), Mendelson et al.
patent: 5130430 (1992-07-01), Shaw
patent: 5198459 (1993-03-01), Imperato et al.
patent: 5232934 (1993-08-01), Downs
patent: 5488056 (1996-01-01), Bodick et al.
patent: 5556837 (1996-09-01), Nestler et al.
patent: 5556838 (1996-09-01), Mayer et al.
patent: 5574052 (1996-11-01), Rose et al.
patent: 5762925 (1998-06-01), Sagen
patent: 5911992 (1999-06-01), Braswell et al.
patent: 5969156 (1999-10-01), Briggs et al.
patent: 5985864 (1999-11-01), Imai et al.
patent: 6109269 (2000-08-01), Rise et al.
patent: 6121261 (2000-09-01), Glatt et al.
patent: 6194000 (2001-02-01), Smith et al.
patent: 6204284 (2001-03-01), Beer et al.
patent: 6245911 (2001-06-01), Imai et al.
patent: 6372919 (2002-04-01), Lippa et al.
patent: 6569887 (2003-05-01), Lippa et al.
patent: 6716868 (2004-04-01), Lippa et al.
patent: 2004/0102638 (2004-05-01), Russell et al.
patent: 2004/0127541 (2004-07-01), Codd et al.
patent: 2004/0132797 (2004-07-01), Lippa et al.
patent: 2004/0157869 (2004-08-01), Lippa et al.
patent: 2004/0157870 (2004-08-01), Lippa et al.
patent: 858683 (1982-12-01), None
patent: 893707 (1982-12-01), None
Miller et al., J. Chrom. A (1999), vol. 865, pp. 211-226.
Baldessarini, R.Drugs and The Treatment of Psychiatric Disorders. Goodman & Gilman's The Pharmacological Basis of Therapeutics 9thEdition. Hardman et al. eds. 1996. p. 399 and ch 18:431-459, McGraw-Hill, New York.
Blum, et al.,Dopamine D2 Receptor Gene Variants; Association and Linkage Studies In Impulsive-Addictive-Compulsive Behavior. Pharmacogenetics 5:121-141, 1996.
Bray, G.A Concise Review On The Therapeutics of Obesity. Nutrition 16:953-960; 2000.
Crown, W.Economic Outcomes Associated With Tricyclic Antidpressant and Selective Serotonin Reuptate Inhibitor Treatments For Depression. Acta Psychiatr. Supp. 2000; 403:62-6.
D'Aquila, et al,The Role Of Dopoamine In The Mechanism of Action of Antidepressant Drugs. Eur. J. Pharmacol. 405:365-373, 2000.
Epstein, et al.,1-ARYL-3-AZABICYCLO[3.1.0]HEXANES, A New Series of Non-Narcotic Analgesic Agents. J. Med. Chem. 24(5):481-90, 1981.
Epstein, et al.,Bicifadine: Non-Narcotic Analgesic Activity of 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES. NIDA Res. Monogr. 41:93-98, 1982.
Frazer, A.Norepinephrine Involvement In Antidepressant Action. J. Clin. Psychiatry. 61(10):25-30, 2000.
Fredman, et al.,Partial Response. Nonresponse, and Relapse With Selective Serotonin Reuptake Inhibitors In Major Depression: A Survey of Current “Next-Step”Practices. J. Clin. Psychiatry 61(6):403-8, 2000.
Hackh's Chemical Dictionary, 4thEdition, 1969, Julius Grant, ed., McGraw-Hill Book Company, New York, pp. 474-75.
Harrison's Principles of Internal Medicine 2485-2503 (Fauci, et al., eds., 14thed. 1998).
Hitri, et al.,Molecular, Functional and Bilchemical Characteristics of The Dopamine Transporter: Regional Differences and Clinical Relevance. J. Clin. Pharmacol. 17:1-22, 1994.
Hoffman, et al.,Localization and Dynamic Regulation of Biogenic Amine Transporters In The Mammalian Central Nervous System. Front. In Neuroendocrinol. 19(3): 187-213, 1998.
Kiyatkin, E.Dopamine Mechanisms of Cocaine Addition; Int. J. Neurosci. 78:75-101, 1994.
Kreek, M.Cocaine, Dopamine and The Endogenous Opiod System. J. Addict. Dis. 15:73-96, 1996.
Leonhardt, et al.,New Approaches In The Pharmacological Treatment of Obesity. Eur. J. Nutr. 38:1-13, 1999.
Meyerson, et al.,Allosteric Interation Between The Site Labeled by [3H]imipramine and The Serotonin Transporter In Human Platelets. J. Neurochem. 48(2):560-65, 1987.
Nagatsu, et al.,Changes In Cytokines And Neorotrophins In Parkinson's Disease. J. Neural. Transm. Suppl. 60:277-290, 2000.
Noble, E.Polymorphisms of The D2 Dopamine Receptor Gene and Alcoholism and Other Substance Use Disorders. Alcohol. Supp. 2:35-43, 1994.
Porter, et al.,Single Dose Comparison of Bicifadine, Codeine, and Placebo in Postoperative Pain. Current Therapeutic Research. 30(3):156-160, Aug. 1981.
Scates, et al.,Reboxetine: A Selective Norepinephrine Reuptate Inhibitor For The Treatment Of Depression. Ann. Pharmacother. 34(11):1302-12, 2000.
Simon, et al.,TCAs or SSRIs As Initial Therapy For Depression?J. of Family Practice. 48:845-46, 1999.
Stacy, et al.,Treatment Options for Early Parkinson's Disease. Am. Fam. Phys. 53:1281-87, 1996.
Sullivan, et al.,Mechanisms of Appetite Modulation By Drugs, Federation Proceedings, vol. 44, No. 1, Part 1, pp. 139-144, 1985.
Wang, et al.,The Oral Analgesic Efficacy of Bicifadine Hydrochloride In Postoperative Pain. J. Clin. Pharmacol. 22(4):160-164, Apr. 1982.
Wong, et al.,Reboxetine: A PharmacologicallyPotent, Selective, and Specific Norepinephrine Reuptake Inhibitor. Biol. Psychiatry. 47(9):818-29, 2000.

Affiliated with

Also associated with

Rating

(−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3610319